Biopharma companies develop medicines, vaccines and advanced therapies to prevent, treat and manage disease. The sector spans drug discovery, clinical development, manufacturing and commercialisation across a wide range of therapeutic areas.
This category includes companies working on:
Browse 304 UK biopharma companies below.
Clinical-stage antibody-drug conjugate developer for cancer
Iksuda Therapeutics is a clinical-stage biotechnology company developing antibody-drug conjugates for difficult-to-treat cancers. Its platform combines stable bioconjugation chemistry with tumour-selective payload activation to improve therapeutic index. Clinical programmes include IKS014, a HER2-targeting ADC, and…
Novel small-molecule therapeutics for neurodegenerative diseases
Nevrargenics is a UK-based biotech company developing novel small-molecule therapeutics for neurodegenerative diseases. Spun out of Durham University and built on research collaboration with the University of Aberdeen, the company uses a patented library of dual-activity retinoic acid receptor modulators designed to…
UK manufacturer of over-the-counter liquid medicines and own-label remedies
Bell's Healthcare is a pharmaceutical manufacturer producing over-the-counter medicines, with a focus on liquid formulations such as cough syrups and cold and flu remedies. It markets products under its own brand and manufactures own-label medicines for pharmacy chains and retailers at a licensed, GMP-compliant…
Gene therapy company targeting complement-mediated ocular diseases
Complement Therapeutics is a clinical-stage biotechnology company developing gene therapies and protein-based therapeutics for diseases driven by dysregulation of the complement immune pathway. A spin-out from the University of Manchester, the company's lead programme CTx001 is an AAV-based gene therapy for geographic…
Allergen immunotherapies for hay fever and food allergy
Allergy Therapeutics is a commercial biopharmaceutical company developing, manufacturing and selling immunotherapies that address the underlying immune cause of allergic disease. Its marketed products, sold across Europe, include short-course subcutaneous treatments for pollen and other respiratory allergies,…
Oral iron deficiency therapy for adults across multiple indications
Shield Therapeutics is a commercial-stage specialty pharmaceutical company focused on iron deficiency. Its lead product, Accrufer/Feraccru (ferric maltol), is an oral iron therapy approved for adults with iron deficiency with or without anaemia. The product is commercialised in the US with Viatris and licensed to…
Micellar oral cannabidiol formulation for psychiatric drug development
NWPharmaTech is a clinical-stage biotechnology company developing investigational oral cannabidiol formulations for psychiatric disorders. Its NWPT-SM32300 programme uses a high-loading micellar softgel intended to deliver consistent oral doses. The company reports completion of a Phase 1 pharmacokinetic and…
Antibody fragment drug conjugate platform for solid tumour oncology
Antikor Biopharma is a pre-clinical stage biotechnology company developing antibody fragment drug conjugates for the treatment of solid tumours. The company's proprietary platform uses smaller antibody fragments rather than whole antibodies to achieve improved tumour penetration and faster systemic clearance compared…
Multimodal small molecule therapeutics for neurodegenerative disease
Elixa MediScience is a UK drug discovery company developing novel small molecule compounds designed to slow the progression and delay the onset of neurodegenerative diseases including Alzheimer's, Parkinson's and multiple sclerosis. The company's approach targets multiple pathophysiological mechanisms simultaneously,…
ECM-targeted drug discovery platform for fibrosis and solid tumours
Engitix is a preclinical-stage biotechnology company developing therapeutics that target the extracellular matrix (ECM) in fibrosis and solid tumours. Its proprietary discovery platform integrates one of the largest ECM bioarchives with AI and machine learning to identify disease-specific targets and biomarkers.…
Programmable cell-killing particle platform for targeted therapeutic delivery
Granza Bio is a biotechnology company developing a cell-targeted delivery platform based on supramolecular attack particles, naturally occurring structures used by cytotoxic T cells and natural killer cells to deliver lethal payloads with precision. The company is engineering programmable versions of these particles,…
AAV gene therapy for Bardet-Biedl syndrome and genetic obesity
Axovia Therapeutics is a biotechnology company developing adeno-associated viral gene therapies for inherited ciliopathies and genetic obesity. Its lead candidate delivers a functional BBS1 gene into retinal cells to investigate treatment of vision loss associated with Bardet-Biedl syndrome. A first-in-human, early…
Precision medicines targeting protein isoforms for neuromuscular disease
ISOgenix is a biotechnology company developing precision medicines that target disease-relevant protein isoforms for neuromuscular and neurological conditions. The company's approach focuses on identifying and modulating specific isoforms produced through alternative gene splicing and epigenetic regulation, aiming to…
Enzymatic wound debridement therapy derived from maggot biology
SolasCure is a biotechnology company developing a recombinant enzyme-based hydrogel for the treatment of chronic wounds. The lead product contains a protease cloned from medical maggots that degrades non-viable wound tissue including fibrin, elastin, and collagen to prepare the wound bed for healing. The product is in…
Oncology biotech developing peptide therapeutics and diagnostics
ValiRx is a UK-listed biopharmaceutical company focused on the development of oncology therapeutics and companion diagnostics. The company selects and incubates novel drug candidates, including peptide-based compounds targeting prostate cancer, endometriosis, and other solid tumours, progressing them from preclinical…
AAV gene therapy platform targeting podocyte-mediated kidney disease
Purespring Therapeutics is a clinical-stage biotech developing AAV-based gene therapies for chronic kidney disease. Its platform delivers therapeutic transgenes directly to podocytes, specialised cells implicated in the majority of renal diseases, enabling disease-modifying treatment of both rare monogenic and more…
Engineered T cell receptor therapies for solid tumour cancers
Adaptimmune is a clinical-stage biopharmaceutical company developing engineered T cell receptor therapies targeting solid tumours. The company's T-cell platform engineers T cell receptors with enhanced affinity for cancer-associated antigens, enabling immune recognition of tumour cells that evade conventional…
Biomarker-guided therapeutics for psychosis-related cognitive impairment
Monument Therapeutics is a clinical-stage biopharmaceutical company developing stratified treatments for neuropsychiatric conditions. Its lead programme, MT1988, is being evaluated in people at clinical high risk of psychosis. A randomised, placebo-controlled Phase 1/2 study dosed its first participant in March 2026…
Mitochondrial sulfide-donor therapeutics for obesity and myopathies
MitoRx Therapeutics is a company developing first-in-class small molecule therapeutics that target mitochondrial sulfide signalling, a mechanism implicated in metabolic dysfunction and muscle disease. Its lead programme is an injectable mitochondria-targeted sulfide donor designed to achieve fat loss without lean mass…
Takeda's UK clinical development and drug discovery operations
Takeda UK encompasses the British operations of Takeda Pharmaceutical Company, one of the world's largest biopharmaceutical companies. The London-based Takeda Development Centre Europe leads clinical development, regulatory affairs, and medical affairs across oncology, neuroscience, gastrointestinal disease, rare…